Neuraxis, INC (NRXS) stock: key figures, P/E, revenue and dividend
Health Care · United States · ISIN US64134X2018
Neuraxis, INC financials
| Fiscal year | 2025 |
|---|---|
| Revenue | 3.57 m USD |
| Gross profit | 3.01 m USD |
| Operating income | -7.83 m USD |
| EBIT | -7.73 m USD |
| Net income | -7.80 m USD |
| Diluted EPS – continuing operations | -0.95 USD |
Full history since 2020, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About Neuraxis, INC
NeurAxis, Inc., a medical technology company, focuses on developing neuromodulation therapies to address chronic and debilitating conditions in children and adults in the United States. It offers IB-Stim, a percutaneous electrical nerve field stimulation system intended to be used in patients 8 years of age with functional abdominal pain associated with irritable bowel syndrome (IBS), functional dyspepsia (FD) and associated FD nausea symptoms. The company also offers rectal expulsion device, a screening tool that helps to detects evacuation disorders. It sells its products to healthcare companies, such as hospitals and clinics. The company was formerly known as Innovative Health Solutions, Inc. and changed its name to NeurAxis, Inc. in March 2022. NeurAxis, Inc. was founded in 2011 and is headquartered in Carmel, Indiana.
More stocks
- Endava Ltd (DAVA)
- Kumpulan Kitacon Berhad (5310.KL)
- Componenta Corp (CTH1V.HE)
- Awale Resources Ltd (ARIC.V)
- R F INDUSTRIES LTD (RFIL)
- XAC Automation (5490.TWO)
- EDU Holdings Ltd (EDU.AX)
- IEVA GROUP S.A. (ALIEV.PA)
- Dicot AB (DICOT.ST)
- Hwaseung Corporation Co Ltd (013520.KS)
- Lucent, Inc. (LUCN)
- Daejung Chemicals & Metals Co.Ltd (120240.KQ)
Not investment advice. All data without warranty, price as of 13.11.2026. Details in the risk notice.